Biophytis and LynxKite Expand AI Partnership for Longevity Drug Discovery

The alliance aims to accelerate the development of next-generation therapies targeting sarcopenia and age-related macular degeneration.

Mar. 13, 2026 at 8:38pm

Got story updates? Submit your updates here. ›

Biophytis SA, a clinical-stage biotechnology company focused on age-related diseases, and LynxKite Technologies, a leader in advanced analytics and AI, have expanded their partnership to turbocharge AI-driven drug discovery for longevity therapeutics. The collaboration will leverage LynxKite's computational platform and AI expertise to support Biophytis' drug development programs targeting sarcopenia, a degenerative muscle disease associated with aging, and dry age-related macular degeneration.

Why it matters

The partnership aims to accelerate the discovery and development of much-needed therapies for age-related diseases that affect millions of elderly people worldwide. By combining Biophytis' clinical expertise with LynxKite's innovative AI capabilities, the alliance seeks to drive breakthroughs in longevity research and bring transformative treatments to patients.

The details

The expanded partnership will focus on several key objectives, including modeling the Mas receptor for structure-based drug design using AI and protein prediction tools, designing and prioritizing synthetic drug candidates through AI-guided molecule generation and predictive filtering, synthesizing and testing promising MasR activators, and selecting and protecting lead candidates through patent filings. The collaboration will also involve developing and validating the AI software through feedback loops from in vitro and in vivo validation of candidates.

  • The partnership was announced on March 13, 2026.

The players

Biophytis SA

A clinical-stage biotechnology company focused on developing drug candidates for age-related diseases, including sarcopenia and age-related macular degeneration.

LynxKite Technologies

A leader in advanced analytics and artificial intelligence, known for its flagship open-source platform LynxKite, which will be used to integrate AI computational methods relevant for longevity research.

Stanislas Veillet

The CEO of Biophytis.

Gyorgy Lajtai

The CEO of LynxKite.

Nebius

An AI cloud company that is building a platform for developers and companies to take charge of their AI future, and is providing cloud computing resources for the partnership.

Got photos? Submit your photos here. ›

What they’re saying

“The launch of MASSIVE marks a decisive step in our longevity strategy, combining our clinical expertise with LynxKite's innovative AI to accelerate the discovery of transformative therapies against sarcopenia.”

— Stanislas Veillet, CEO of Biophytis (PR Newswire)

“We are proud to collaborate with Biophytis on pioneering computational longevity through our LynxKite platfom, which demonstrates how LynxKite can revolutionize discovery by designing, integrating and orchestrating relevant computational tools in diverse modalities.”

— Gyorgy Lajtai, CEO of LynxKite (PR Newswire)

What’s next

The partnership plans to expand the AI-driven drug discovery platform to target additional age-related diseases beyond sarcopenia and dry age-related macular degeneration.

The takeaway

This collaboration between Biophytis and LynxKite represents a promising approach to accelerating the development of much-needed therapies for age-related diseases, leveraging the power of AI to drive innovation in the longevity research field.